Explore

Trendline Trendline
Merck Discontinues TROP ADC Development Amid Strategic Shifts

Merck Discontinues TROP ADC Development Amid Strategic Shifts

Merck Discontinues TROP ADC Development Amid Strategic Shifts
Trendline Trendline
Merck Discontinues Early-Stage TROP ADC Amid Strategic Shifts in Oncology

Merck Discontinues Early-Stage TROP ADC Amid Strategic Shifts in Oncology

Merck Discontinues Early-Stage TROP ADC Amid Strategic Shifts in Oncology
Reuters Reuters
Big Pharma M&A set for mega year as patent expiries drive deal urgency

Big Pharma M&A set for mega year as patent expiries drive deal urgency

By Christy Santhosh and Sriparna Roy May 1 (Reuters) - Biotech dealmaking is on pace for a bumper year in 2026, with large drugmakers on an acquisition spree to boost their pipelines ahead of upcoming patent losses.
Trendline Trendline
Pfizer's ELREXFIO Shows Promise in Treating Relapsed Multiple Myeloma

Pfizer's ELREXFIO Shows Promise in Treating Relapsed Multiple Myeloma

Pfizer's ELREXFIO Shows Promise in Treating Relapsed Multiple Myeloma
Trendline Trendline
Merck Reports Strong Q1 Results Driven by Keytruda Sales, Adjusts 2026 Outlook

Merck Reports Strong Q1 Results Driven by Keytruda Sales, Adjusts 2026 Outlook

Merck Reports Strong Q1 Results Driven by Keytruda Sales, Adjusts 2026 Outlook
Trendline Trendline
Bicycle Therapeutics Advances Cancer Drug Development with Promising Clinical Data

Bicycle Therapeutics Advances Cancer Drug Development with Promising Clinical Data

Bicycle Therapeutics Advances Cancer Drug Development with Promising Clinical Data
Trendline Trendline
AstraZeneca Exercises Option to License Pinetree Therapeutics' EGFR Degrader Program, Triggering $25M Payment

AstraZeneca Exercises Option to License Pinetree Therapeutics' EGFR Degrader Program, Triggering $25M Payment

AstraZeneca Exercises Option to License Pinetree Therapeutics' EGFR Degrader Program, Triggering $25M Payment
Trendline Trendline
Moderna's mRNA-4359 and Merck's Keytruda Show Promising Results in Melanoma Treatment

Moderna's mRNA-4359 and Merck's Keytruda Show Promising Results in Melanoma Treatment

Moderna's mRNA-4359 and Merck's Keytruda Show Promising Results in Melanoma Treatment
Trendline Trendline
Moderna and Marengo Present Promising Cancer Combo Therapies at AACR 2026

Moderna and Marengo Present Promising Cancer Combo Therapies at AACR 2026

Moderna and Marengo Present Promising Cancer Combo Therapies at AACR 2026
Trendline Trendline
AbbVie Secures Option to Acquire Kestrel Therapeutics for $1.45 Billion in KRAS Inhibitor Deal

AbbVie Secures Option to Acquire Kestrel Therapeutics for $1.45 Billion in KRAS Inhibitor Deal

AbbVie Secures Option to Acquire Kestrel Therapeutics for $1.45 Billion in KRAS Inhibitor Deal
Trendline Trendline
Pharmaceutical Companies Announce Key Board Appointments to Strengthen Leadership

Pharmaceutical Companies Announce Key Board Appointments to Strengthen Leadership

Pharmaceutical Companies Announce Key Board Appointments to Strengthen Leadership
Trendline Trendline
Eli Lilly's Aggressive M Strategy Surpasses $21 Billion in 2026

Eli Lilly's Aggressive M Strategy Surpasses $21 Billion in 2026

Eli Lilly's Aggressive M Strategy Surpasses $21 Billion in 2026